LIVEN · Liven Pharma Limited
Transmission of Annual Report for the Year Ended June 30, 2026
- Filed
- 5 October 2026 at 8:03 am
- Category
- Financials
- Sentiment
- Neutral
- Impact
- High
AI executive summary
Liven Pharma Limited reported its annual financial results for the year ended June 30, 2026, recording a net loss after tax of PKR 31.139 million compared to a loss of PKR 584.459 million in the previous year. The Board has decided to withhold dividend distribution for the year in light of prevailing financial headwinds and to prioritize business growth.
Key takeaways
- Net turnover for the year ended June 30, 2026, stood at PKR 105.807 million compared to PKR 127.272 million in FY2025.
- Loss after tax narrowed significantly to PKR 31.139 million from PKR 584.459 million in the previous year.
- Loss per share (basic and diluted) improved to Rs. 0.28 compared to Rs. 7.11 (restated) in FY2025.
- The Board of Directors elected to withhold dividend distribution for the financial year due to ongoing financial headwinds.
- Profit before taxation was reported at a loss of PKR 66.321 million for FY2026 compared to a loss of PKR 492.187 million in FY2025.
Filing details
Financial results
Annual · Audited · Standalone · 30 June 2026
Figures in Rupees
Reporting period
Year
- Income
- 105,806,555 (prior 127,271,949)
- Profit after tax
- -31,138,687 (prior -584,459,523)
- EPS
- -0.28 (prior -7.11)
- Withheld dividend distribution for the financial year ended June 30, 2026.
- Completed right issue process, increasing paid-up share capital to 113,040,367 ordinary shares.
Dividend and entitlement
- Type
- None
- Notes
- The document is solely for the transmission of Annual Financial Statements and does not declare any cash dividend, bonus, or right shares.
- #annual report
- #financial results
- #liven pharma
- #earnings
This summary is AI-generated and may contain errors or omissions. Review the official PSX filing before making an investment decision.